Merck & Co., Inc. (NYSE:MRK) Shares Sold by Main Street Financial Solutions LLC

Main Street Financial Solutions LLC trimmed its holdings in Merck & Co., Inc. (NYSE:MRKFree Report) by 3.8% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 31,580 shares of the company’s stock after selling 1,247 shares during the period. Main Street Financial Solutions LLC’s holdings in Merck & Co., Inc. were worth $3,443,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also recently added to or reduced their stakes in MRK. AMG National Trust Bank grew its position in shares of Merck & Co., Inc. by 3.4% during the fourth quarter. AMG National Trust Bank now owns 38,306 shares of the company’s stock worth $4,176,000 after acquiring an additional 1,269 shares during the last quarter. Missouri Trust & Investment Co lifted its stake in Merck & Co., Inc. by 24.1% during the fourth quarter. Missouri Trust & Investment Co now owns 10,372 shares of the company’s stock valued at $1,131,000 after buying an additional 2,012 shares in the last quarter. Allegheny Financial Group LTD increased its holdings in shares of Merck & Co., Inc. by 2.4% in the 4th quarter. Allegheny Financial Group LTD now owns 32,576 shares of the company’s stock valued at $3,551,000 after purchasing an additional 774 shares during the period. Hamel Associates Inc. increased its holdings in shares of Merck & Co., Inc. by 2.3% in the 4th quarter. Hamel Associates Inc. now owns 89,744 shares of the company’s stock valued at $9,784,000 after purchasing an additional 2,033 shares during the period. Finally, Financial Advocates Investment Management increased its holdings in Merck & Co., Inc. by 3.1% in the fourth quarter. Financial Advocates Investment Management now owns 25,831 shares of the company’s stock worth $2,816,000 after buying an additional 780 shares during the last quarter. 76.07% of the stock is owned by institutional investors and hedge funds.

Merck & Co., Inc. Stock Performance

NYSE:MRK traded up $0.31 during trading hours on Friday, reaching $131.19. The stock had a trading volume of 8,281,595 shares, compared to its average volume of 7,287,899. The company has a debt-to-equity ratio of 0.77, a quick ratio of 0.99 and a current ratio of 1.25. The stock has a 50 day simple moving average of $127.27 and a 200 day simple moving average of $118.73. Merck & Co., Inc. has a 12-month low of $99.14 and a 12-month high of $133.10. The stock has a market cap of $332.28 billion, a P/E ratio of 145.77, a price-to-earnings-growth ratio of 1.68 and a beta of 0.39.

Merck & Co., Inc. (NYSE:MRKGet Free Report) last announced its quarterly earnings data on Thursday, April 25th. The company reported $2.07 earnings per share for the quarter, beating analysts’ consensus estimates of $1.94 by $0.13. The company had revenue of $15.78 billion for the quarter, compared to analysts’ expectations of $15.21 billion. Merck & Co., Inc. had a return on equity of 14.05% and a net margin of 3.76%. Merck & Co., Inc.’s revenue for the quarter was up 8.9% compared to the same quarter last year. During the same period last year, the firm posted $1.40 EPS. On average, research analysts forecast that Merck & Co., Inc. will post 8.69 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

MRK has been the topic of several analyst reports. Cantor Fitzgerald reiterated an “overweight” rating and set a $135.00 price target on shares of Merck & Co., Inc. in a report on Thursday, April 18th. TheStreet cut Merck & Co., Inc. from a “b+” rating to a “c+” rating in a research report on Monday, March 4th. StockNews.com upgraded Merck & Co., Inc. from a “buy” rating to a “strong-buy” rating in a research note on Friday, February 2nd. Berenberg Bank raised their target price on Merck & Co., Inc. from $140.00 to $143.00 and gave the company a “buy” rating in a research note on Monday, April 8th. Finally, Societe Generale lowered Merck & Co., Inc. from a “hold” rating to a “sell” rating and set a $104.00 price objective for the company. in a research report on Monday, March 11th. One investment analyst has rated the stock with a sell rating, three have given a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $131.33.

Read Our Latest Analysis on Merck & Co., Inc.

Merck & Co., Inc. Profile

(Free Report)

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names.

Recommended Stories

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRKFree Report).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.